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Background: The goal of our study was to determine the therapeutic effects of thymoquinone in a dose-
dependent manner in a model of neuropathic pain following an experimentally applied spinal cordKey words:
heat-cold allodynia
mechanical allodynia
neuropathic pain
thymoquinone3X/$ - see front matter & 2014. The Authors.
x.doi.org/10.1016/j.curtheres.2013.11.001
is an open-access article distributed unde
ns Attribution-NonCommercial-ShareAlike L
rcial use, distribution, and reproduction in
author and source are credited.
ress correspondence to: Feyzi Çelik, MD, Ane
ent, Dicle University Faculty of Medicine, 21
ail address: drfeyzicelik@gmail.com (F. Çelik).a b s t r a c t
injury (SCI).
Methods: Fifty female adult Wistar albino rats weighing between 220 and 260 g were included in the
study and were divided into 5 groups as follows: Group S (sham), Group C (control), Group T100
(100 mg/kg thymoquinone), Group T200 (200 mg/kg thymoquinone), and Group T400 (400 mg/kg
thymoquinone). To begin the experiment, SCI was applied to all groups (with the exception of the sham
group) following a mechanical and heat–cold test. Two weeks later, the mechanical and heat–cold tests
were repeated, and a single normal saline dose was given to the sham and control groups, whereas
3 varying doses of thymoquinone were given to the other groups. The mechanical and heat–cold tests
were repeated at 30, 60, 120, and 180 minutes after receiving thymoquinone. Finally, the animals were
put to death via the removal of intracardiac blood. The levels of nitric oxide, total oxidant status, total
antioxidant status, paraoxonase, malondialdehyde, tumor necrosis factor-α, and interleukin-1β were
determined in all of the blood samples.
Results: The withdrawal threshold and withdrawal latency values recorded from the mechanical and
heat–cold allodynia measurements for all 3 thymoquinone groups were higher than that of the control
group at all time points (ie, 30, 60, 120, and 180 minutes). There were no differences in these results
between the 3 thymoquinone groups. The paraoxonase and total antioxidant status serum levels of all
3 thymoquinone groups were higher than those of the control group, whereas total oxidant status, nitric
oxide, malondialdehyde, interleuken-1β, and tumor necrosis factor-α levels were lower in the 3 thymo-
quinone groups than in the control group.
Conclusions: Thymoquinone is beneﬁcial for decreasing experimental neuropathic pain following SCI.
However, increasing the dose does not change the effect.
& 2014. The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Neuropathic pain affects millions of people worldwide.1 It is a
chronic type of pain that worsens as it continues, and can range
from mild to extreme pain levels. It can develop following illnesses
of the peripheral or central nervous systems, and can also develop
as a result of an injury. Despite the many experimental and animalPublished by Elsevier Inc. All right
r the terms of the Creative
icense, which permits non-
any medium, provided the
sthesiology and Reanimation
280 Diyarbakir, Turkey.studies on neuropathic pain, its pathophysiologic mechanisms
have not been completely elucidated.
Pain that occurs due to a spinal cord injury (SCI) can diminish
quality of life and hinder successful physical rehabilitation. Neuro-
pathic pain is difﬁcult to relieve. Many patients have failed to
beneﬁt from current medications, and therefore there is a need to
develop new medications.2
Thymoquinone is extracted from the oil of Nigella sativa, and in
recent studies it has been reported to be immunomodulatory,3
anti-inﬂammatory,4 antitumor,5 antidiabetic,6,7 and antinocicep-
tive.8 However, the effects of thymoquinone have not yet been
determined for neuropathic pain following SCI.
Generally, neuropathic pain is monitored with mechanical9,10
and heat–cold8,11 allodynia tests, although it can be detected via
biochemical parameters as well.6s reserved.
F. Çelik et al. / Current Therapeutic Research 76 (2014) 11–1612Our study was conducted to determine the dose-dependent
therapeutic effects of PO thymoquinone in a model of neuropathic
pain.Methods
Animals
Following approval from our ethics committee, 50 female adult
Wistar albino rats weighing between 220 and 260 g with normal
motor activity were selected from the Dicle University Health
Research Center. The animals were kept under standard laboratory
conditions (ie, exposed to light from 12:00 pm to 12:00 am at a
room temperature of 201C–221C) during the duration of the
experiment (2 weeks). The rats were fed ad libitum. Their bladders
were emptied twice a day via manual compression. During the
experiment, none of the animals developed infections or paralysis
of the back legs following cord trauma, and none displayed
dragging behaviors.Experimental protocol
The rats were equally divided into 5 random groups: Group S:
Sham þ normal saline (NS), Group C: SCI þ NS, Group T100: SCI þ
thymoquinone 100 mg/kg/PO, Group T200: SCI þ thymoquinone 200
mg/kg/PO, and Group T400: SCI þ thymoquinone 400 mg/kg/PO.
All groups were subjected to mechanical and heat–cold tests
before the start of the experiment. With the exception of the sham
group, SCI was applied to all of the animals. Two weeks later, the
mechanical and heat–cold tests were repeated, and the sham and
control groups were given a single dose of NS, whereas the other
groups were given the appropriate dose of thymoquinone (Sigma
catalog-274666; Cas No. 490-91-5, in sterile packaging) in NS by
nasogastric feeding tube. Doses of thymoquinone were chosen
according to the study by Abdel-Fattah et al.8 The mechanical and
heat–cold hypersensitivity tests were repeated at 30, 60, 120, and
180 minutes after receiving NS or thymoquinone. After all animals
were anesthetized (using 80 mg/kg ketamine), they were put to
death after 180 minutes by removal of intracardiac blood and
perfusion of NS with 10% formaldehyde.SCI
Anesthesia (80 mg/kg ketamine) was administered intraperi-
toneally to all rats in a manner that ensured the preservation of
spontaneous breathing. Using interscapular distance as a refer-
ence, a 3  2 cm area on each animal’s back was shaved, and local
antiseptic (povidone-iodine) was applied. Then, lidocaine was
administered as local anesthetic, which passed the cutaneous
and subcutaneous tissue at the T5–12 levels. While under anes-
thesia, the rats were placed in a facedown position and were
monitored with a rectal heat probe to maintain a body temper-
ature of 371C. The paravertebral muscle fascia were pulled apart
using lateral blunt dissection until the T6–7 lamina could be seen.
A total laminectomy was carefully applied at a single level to
prevent damage to the dura. A Yaşargil aneurysm clip (model FE
721 K; Aesculap AG and Co, Tuttlingen, Germany) for standard
trauma was clipped around the dura and spinal cord between T6–7
for 1 minute with 63 g force.12 Then, the clip was removed and
following hemostasis the incision area was closed with 3-0 silk
sutures appropriate for anatomic layers. The rats were then placed
in their cages.Tests
Mechanical test
The withdrawal threshold measurement, which is the most
common method used to measure mechanical allodynia, was
taken with an electronic von Frey device (Model EVF3; Bioseb,
Chaville, France). For the test, every rat was placed on a mesh ﬂoor
inside a transparent plastic cage. The rats were kept in a silent
environment at room temperature for 20 minutes, and then force
(in grams) was applied to the rats through the plantar hind paw
up-down method.13 The upper pressure limit was 15 g, and the
point at which each rat pulled its paw back was recorded. This test
determined the mechanical excitability threshold.
Heat (8)–cold (44) test
Flicking of the hindlimb or jumping as the withdrawal latency
measurement, which is the most commonly used method to
measure heat–cold allodynia using a hot–cold plate analgesia
meter (Cold Hot Plate Test; Bioseb, Chaville, France), was meas-
ured. The plate can be heated to 651C or cooled to 31C (70.11C)
in ambient room temperature (20oC–25oC). Each animal was
placed in a Plexiglas cylinder (165 mm diameter  25 mm height)
with a drilled cover.11 A temperature of 55oC (71oC) was used to
determine heat hypersensitivity, and a cut-off time of 60 seconds
was used to prevent tissue damage. A temperature of 3oC was
chosen to determine cold hypersensitivity.14,15
Biochemical analysis
Blood samples were immediately centrifuged at 4000 rpm (4oC
for 10 minutes), transferred into Eppendorf tubes (Relassay, Gaz-
iantep, Turkey), and were kept at 70oC until the end of the study,
which was completed in 3 months. Total antioxidant status (TAS)
and total oxidant status (TOS) were measured by Erel’s meth-
ods,16,17 whereas malondialdehyde (MDA) content was measured
using a spectrophotometer, as previously described.18 Serum para-
oxonase (PON) levels were measured using a spectrophotometer
with a modiﬁed Eckerson method. Initial rates of paraoxon hydrol-
ysis (0.0-diethyl-0-p-nitrophenylphosphate; Sigma Chemical Co,
London, United Kingdom) were determined by measuring liberated
p-nitrophenol at 405 nm (371C).19 Plasma nitric oxide (NO; Cayman
Chemicals, Ann Arbor, Michigan), tumor necrosis factor-α (TNF-α;
Bender MedSystems, Vienna, Austria), and interleukin-1β (IL-1β;
Bender MedSystems, Vienna, Austria) levels were determined with
an enzyme-linked immunosorbent assay method.
Statistical analysis
Statistical analyses were performed using SPSS for Windows
13.0 (IBM-SPSS Inc, Armonk, New York). Biochemical values are
presented as mean values (SD). Differences between groups were
compared with the nonparametric Kruskal-Wallis test. A Mann-
Whitney U test was used for binary comparisons. The Bonferonni
correction was applied, and Ps o 0.01 were considered to be
statistically signiﬁcant.Results
The withdrawal threshold and withdrawal latency values
recorded from the mechanical and heat–cold allodynia measure-
ments for all 3 thymoquinone groups were higher than that of the
control group at all time points (ie, 30, 60, 120, and 180 minutes)
(P o 0.01). There were no differences in these results between the
3 thymoquinone groups (ie, T100, T200, and T400) (Figures 1–3
and Table I).
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Figure 1. Thymoquinone affected the mechanical hypersensitivity of rats with neuropathic pain following spinal cord injury (SCI). Baseline ¼ 2 weeks following SCI and just
before giving the medication; PDA ¼ postdrug administration; Pre SCI ¼ values before the experiment. *Compared with the control group (Group C), the withdrawal
thresholds of all the thymoquinone groups (T100, T200, and T400) increased. However, no difference was found between the thymoquinone groups.
F. Çelik et al. / Current Therapeutic Research 76 (2014) 11–16 13Serum PON and TAS levels in the thymoquinone groups were
higher than those of the control group, whereas serum TOS, NO,
MDA, IL-1β, and TNF-α levels were lower than those of the control
group (P o 0.01) (Table II).Discussion
Patients experiencing neuropathic pain often seek relief from
physicians, who provide many different medications andHeat plate hypersensitivity
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Figure 2. Thymoquinone affected the heat plate hypersensitivity of rats with neuropath
C), the withdrawal latency of all the thymoquinone groups (T100, T200, and T400) increa
¼ 2 weeks following SCI and just before giving the medication; PDA ¼ postdrug admintreatment options.20 Recently, it has been suggested that thymo-
quinone provides immunomodulatory, anti-inﬂammatory, and
antinociceptive effects.3,4,8
Oral administration of N. sativa produces a suppressive effect on
nociceptive responses and the antinociceptive effect of N. sativa oil
is partly attributable to thymoquinone, 1 of its components. It is
assumed that the supraspinal opioid systems are involved in the
antinociceptive effect of thymoquinone.8
Thymoquinone, when administered orally and intraperito-
neally, has positive analgesic effects that cannot be reversed by min PDA 120 min
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Figure 3. Thymoquinone affected the cold plate hypersensitivity of rats with neuropathic pain following spinal cord injury (SCI). Compared with the control group (Group C),
the withdrawal latency of all the thymoquinone groups (T100, T200, and T400) increased. However, no difference was found between the thymoquinone groups. Baseline ¼
2 weeks following SCI and just before giving the medication; PDA ¼ postdrug administration; Pre SCI ¼ values before the experiment.
F. Çelik et al. / Current Therapeutic Research 76 (2014) 11–1614opioid antagonists.4 Thymoquinone has been shown to increase
the pain threshold in experimental diabetic neuropathic therapy.6
A study by Bashir et al21 reported that thymoquinone has analgesic/
antinociceptive effects. In our study, we determined that thymo-
quinone had analgesic/antinociceptive effects on central pain
following SCI. Previous studies have determined the effects of
thymoquinone via mechanical allodynia, heat–cold allodynia, or
biochemical analyses. In our work, we used all 3 forms of analysis,Table I
Mean (SD) values of mechanical hypersensitivity, heat plate hypersensitivity, and cold p
Times Parameter S C
Pre-SCI CPH* 35.95 (6.51) 32.86 (7.1
HPH† 11.05 (1.36) 10.95 (1.
MH‡ 15 15
Baseline CPH 34.33 (6.25) 15.05 (2.
HPH 11.05 (1.36) 3.86 (0.
MH 15 2.67 (0.
PDA 30 min CPH 32.63 (7.90) 14.40 (3.
HPH 10.58 (1.46) 4.99 (1.
MH 15 2.62 (0.
PDA 60 min CPH 34.05 (6.35) 15.05 (2.
HPH 11.05 (1.36) 5.03 (0.
MH 15 2.61 (0.
PDA 120 min CPH 33.14 (7.36) 15.05 (2.
HPH 11.05 (1.35) 4.95 (0.
MH 15 2.59 (0.
PDA 180 min CPH 34.05 (6.34) 15.00 (2.
HPH 11.04 (1.34) 5.06 (0.
MH 15 2.72 (0.
Baseline ¼ 2 weeks following SCI and just before giving the medication; C ¼ control gr
mechanical hypersensitivity; PDA ¼ postdrug administration; Pre-SCI ¼ values before th
¼ thymoquinone 200 mg/kg/PO group; T400 ¼ thymoquinone 400 mg/kg/PO group.
nThymoquinone affected the CPH of rats with neuropathic pain following SCI. Compa
However, no difference was found between the thymoquinone groups.
†Thymoquinone affected the HPH of rats with neuropathic pain following SCI. Compa
increased. However, no difference was found between the thymoquinone groups.
‡Thymoquinone affected the MH of rats with neuropathic pain following SCI. Comp
groups increased. However, no difference was found between the thymoquinone groupwhich strengthens our ﬁnding that thymoquinone has an anti-
nociceptive effect. However, we did not observe a dose-dependent
antinociceptive effect of thymoquinone between 100, 200, and
400 mg/kg. Therefore, our results indicate that the lowest dose of
thymoquinone (ie, 100 mg/kg) is sufﬁcient.
Abdel-Fattah et al8 used doses of thymoquinone between 50
and 400 mg/kg/PO to treat peripheral neuropathy. In our work,
which aimed to alleviate neuropathic pain following SCI, we usedlate hypersensitivity, by thymoquinone dose.
T100 T200 T400
3) 35.65 (7.44) 33.77 (7.48) 34.71 (6.56)
30) 10.95 (1.48) 11.30 (1.62) 10.89 (1.28)
15 15 15
44) 23.38 (2.85) 22.69 (2.92) 22.74 (3.48)
96) 4.38 (0.68) 4.37 (0.74) 3.93 (0.67)
51) 4.47 (1.25) 4.80 (1.54) 4.42 (1.25)
11) 21.57 (2.08) 20.75 (4.38) 21.63 (2.88)
08) 7.22 (1.50) 7.07 (1.78) 5.70 (2.26)
51) 6.79 (1.11) 7.44 (1.46) 6.49 (1.38)
44) 23.38 (2.85) 22.85 (2.92) 22.93 (2.46)
97) 7.49 (0.97) 7.53 (1.06) 7.26 (1.12)
42) 8.60 (1.25) 8.43 (1.59) 7.90 (2.10)
43) 23.36 (2.86) 23.23 (2.73) 23.38 (2.85)
83) 7.17 (1.75) 6.74 (1.97) 6.62 (1.58)
39) 8.75 (1.36) 8.16 (1.43) 8.61 (1.46)
46) 21.88 (1.98) 22.50 (2.02) 21.74 (2.10)
83) 8.53 (0.97) 7.24 (1.11) 7.47 (1.60)
46) 8.13 (1.72) 7.96 (1.65) 7.27 (1.46)
oup; CPH ¼ cold plate hypersensitivity; HPH ¼ heat plate hypersensitivity; MH ¼
e experiment; S ¼ sham group; T100 ¼ thymoquinone 100 mg/kg/PO group; T200
red with Group C, the withdrawal latency of all the thymoquinone groups increased.
red with Group C, the withdrawal latency (seconds) of all the thymoquinone groups
ared with Group C, the withdrawal thresholds (in grams) of all the thymoquinone
s.
Table II
Levels of biochemical markers in the serum of experimental animals, by dose of thymoquinone.
Marker S C T100 T200 T400 P
Mean (SD)
PON 30.67 (4.49) 25.99 (5.68) 78.63 (1.80)*,† 80.15 (3.48)*,† 112.76 (17.98)*,†,‡ o0.01
TAS 0.44 (0.06) 0.04 (0.03)* 2.25 (0.46)*,† 2.88 (0.36)*,† 2.10 (0.42)*,† o0.01
TOS 22.77 (4.86) 34.27 (1.29) 1.31 (1.02)*,† 3.41 (1.61)*,†,‡ 1.94 (1.30)*,† o0.01
IL-1β 1.22 (0.53) 2.48 (1.17)* 1.76 (1.38)*,† 1.82 (1.41)* 1.91 (1.43)* o0.01
TNF-α 0.23 (0.41) 3.57 (3.62)* 0.89 (1.45)*,† 0.45 (0.83)† 0.25 (0.47)‡ o0.01
NO 0.17 (0.04) 0.24 (0.06)* 0.16 (0.25)† 0.19 (0.08)†,‡ 0.19 (0.06)*,†,‡ o0.01
MDA 20.37 (4.54) 37.20 (8.92)* 19.40 (2.49)† 22.20 (2.55)† 20.89 (2.63)† o0.01
C ¼ control group; IL-1β ¼ interleukin-1 β; MDA ¼ malondialdehyde; NO ¼ nitric oxide; PON ¼ serum paraoxonase; S ¼ sham group; T100 ¼ thymoquinone 100 mg/kg/
PO group; T200 ¼ thymoquinone 200 mg/kg/PO group; T400 ¼ thymoquinone 400 mg/kg/PO group; TAS ¼ total antioxidant status; TNF-α ¼ tumor necrosis factor α; TOS
¼ total oxidant status.
nDifferent from S group (P o 0.01).
†Different from C group (P o 0.01).
‡Different from T100 group (Po0.01).
F. Çelik et al. / Current Therapeutic Research 76 (2014) 11–16 15between 100 and 400 mg/kg thymoquinone administered orally.
This dose is well below the oral LD50 for thymoquinone (794.3
mg/kg).22
TNF-α and IL-1β increase inﬂammatory cytokines seen in SCI,
and are related to cell death and degree of inﬂammation.23 TNF-α
is an important mediator in neuropathic pain, whereas IL-1β also
plays an important role in pain modulation. Chvatal et al. and Çelik
et al.24,25 have reported that the tissue involved in spinal cord
trauma has higher levels of TNF-α and IL-1β than does uninjured
tissue. Other experimental studies have reported that thymoqui-
none reduces proinﬂammatory cytokines (TNF-α, interleuken-6,
and IL-1β) in blood and tissues, and protects tissue by reducing
inﬂammation in the blood.26–28 Similar to the literature, we
showed that all 3 groups given thymoquinone (T 100, T 200, and
T 400) had lower levels of TNF-α and IL-1β than did the control
group (Table I).
In an organism, oxidant and antioxidant systems are held in a
tight balance. When positive oxygen capacity is disturbed, leuko-
cytes, inﬂammatory mediators, and free oxygen radicals are
created, which can cause damage at the cellular level.29 PON, an
antioxidant bioscavenger, is responsible for hydrolyzing lipid
peroxides, and also plays a major role in the antioxidant system.30
Previous studies have shown that SCI causes a decrease in the level
of PON.31 In our study, serum PON levels in the thymoquinone
groups were higher than those of the control group and the PON
levels of the T400 group were signiﬁcantly higher than those of
the T100 group. PON levels of the T400 group were higher than
those of the T200 group, but this result is not statistically
signiﬁcant (Table II).
Kanter et al32 reported that as oxidative stress decreases in rats
in a traumatic SCI model, neuron count and morphology normal-
ize. TAS is a collection of enzymatic and nonenzymatic antiox-
idants, whereas TOS is a collection of oxidants. In the body, TAS
works as a basic defense mechanism against the development of
oxidative stress. MDA is a marker of oxidative stress, whereas NO
is a molecule that is characteristic of both oxidants and antiox-
idants. If inducible NO synthase leads to the creation of oxidants in
excess, it can cause an increase in oxidative stress.25,33,34
In our study, although TAS increased in the thymoquinone
groups, TOS, NO, and MDA decreased, indicating that thymoqui-
none reduces cell damage due to oxidative stress (Table II).
We did not study the biochemical parameters of the spinal cord
tissue, which is a limitation of our study. Also, the signiﬁcance of
some of the biomarker ﬁndings after a single dose is unclear. This
is especially important because the purported mechanism for the
primary pharmacodynamics outcome in this model is not clearly
identiﬁed.Conclusions
Thymoquinone was beneﬁcial for decreasing experimental
neuropathic pain following SCI, but better effect was not noticed
with higher doses of this drug. Due to the positive results of our
study, there is a need for additional studies evaluating the use of
thymoquinone for clinical use.Acknowledgments
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